Home › Transthyretin-Related Hereditary Amyloidosis › Massachusetts › Boston
Transthyretin-Related Hereditary Amyloidosis clinical trials in Boston, MA
4 studies for Transthyretin-Related Hereditary Amyloidosis are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RecruitingObservational study
- Research Site, Boston
- Research Site, Boston
- Research Site, Boston
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recruiting
- Massachusetts General Hospital, Boston
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
- Boston University (BU) School of Medicine, Boston
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
RecruitingPhase 3
- Brigham and Women's Hospital, Boston
- Boston University School of Medicine, Boston
Transthyretin-Related Hereditary Amyloidosis trials in other cities
- New York City, NY5 studies
- Los Angeles, CA5 studies
- Baltimore, MD4 studies
- Durham, NC4 studies
- Dallas, TX4 studies
- Portland, OR4 studies
- San Diego, CA4 studies
- Philadelphia, PA4 studies
- Chicago, IL3 studies
- Washington, DC3 studies
- Richmond, VA3 studies
- New Haven, CT3 studies
Other studies in Boston
- Breast Cancer112 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)85 studies
- Metastatic Cancer63 studies
- Colorectal Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.